Core Viewpoint - The study reveals that the natural small molecule Lawsone, derived from the plant Impatiens, can enhance the antitumor activity and stem-like properties of CD8⁺ T cells by modulating the NQO1 enzyme and driving metabolic reprogramming through the pentose phosphate pathway (PPP) [2][3][12]. Group 1: Mechanism of Action - Lawsone hijacks the NQO1 enzyme in T cells, inducing redox cycling that enhances the PPP, thereby conferring unique stem-like properties and mitochondrial adaptability to effector CD8⁺ T cells [3][10]. - The Law-NQO1 signaling axis exhibits a biphasic regulation pattern: initially amplifying PPP activity and mROS levels to drive T cell differentiation, followed by a sustained phase that enhances cell proliferation and maintains stemness [10][14]. Group 2: Clinical Implications - The strategy shows strong clinical translation potential, as simple pharmacological pre-treatment of tumor-specific T cells with Lawsone significantly improves their tumor-killing efficiency and persistence in vivo without notable systemic toxicity [12][15]. - This research highlights NQO1 as a new immune metabolic checkpoint and provides a straightforward, cost-effective optimization strategy for T cell therapy without complex genetic modifications [15].

Core Viewpoint - The 2026 Qi Ji Investment Conference emphasizes the importance of collaboration among government, academia, and industry to drive innovation in the healthcare sector, highlighting China's potential in the biopharmaceutical industry as a new pillar of economic growth [1][32]. Group 1: Event Overview - The conference, themed "Gathering Momentum, Creating New Journeys," took place in Shanghai and attracted nearly 150 guests, including government leaders, academicians, top scientists, and representatives from leading investment institutions [1]. - The event serves as a platform for deepening strategic cooperation between the Songjiang District and Qi Ji Investment, focusing on the integration of technology, industry, and finance [2]. Group 2: Keynote Speeches - Wang Huajie, Secretary of the Songjiang District Committee, highlighted the district's advantages in the life and health sector, particularly in in vitro diagnostics and medical devices, and emphasized the need for innovation-driven development [2]. - Zhang Li, CEO of Qi Ji Investment, discussed the shift from macro narratives to micro values in the healthcare industry, asserting that China's biopharmaceutical sector is entering a period of significant growth, akin to a "Golden Age" [9]. - Song Ruilin, a senior expert from the China Pharmaceutical Innovation Promotion Association, pointed out the challenges faced by innovative drugs in China, advocating for a multi-tiered payment system to support sustainable industry development [12][13]. Group 3: Industry Insights - The conference featured discussions on various topics, including the integration of industry and ecology, cross-border cooperation, and the role of AI in pharmaceuticals [21][22][24][27]. - Participants noted that China's clinical research capabilities have significantly improved, allowing for more flexible collaboration models between domestic and international pharmaceutical companies [25]. - The importance of a multi-faceted capital allocation strategy was emphasized, with discussions on the roles of state-owned funds, market-oriented funds, and financial institutions in supporting innovative drug development [29]. Group 4: Future Directions - The conference concluded with a call for continuous innovation and collaboration within the healthcare ecosystem, aiming to break traditional boundaries and achieve long-term value creation [32].

Group 1 - The first AIC industrial merger fund in China was launched in Shanghai with an initial fundraising scale of 5.702 billion yuan, focusing on key areas of integrated circuit equipment to support industrial mergers and resource integration [2] - The establishment of the AIC industrial merger fund signifies a shift from financial investor to industrial organizer, indicating a more diversified approach to participating in the primary market [2] - The investment logic has evolved from single project focus to cluster-based layouts around industrial chain maps, enhancing the full-cycle service capability of fundraising, investment, management, exit, and nurturing [2] Group 2 - Shanghai is actively developing its merger ecosystem, with government initiatives including a 100 billion yuan integrated circuit design merger fund and a 100 billion yuan biopharmaceutical merger fund to attract market-oriented merger fund managers [3] - The Shanghai municipal government has initiated a 500 billion yuan industrial transformation upgrade fund, targeting new-generation electronic information, high-end equipment, and other key industries [4] - The establishment of a national-level merger fund is expected to mobilize over 1 trillion yuan in various funds, marking a strategic shift towards market-driven mergers and industry integration [5][6] Group 3 - The current landscape of China's merger funds presents a historic structural development opportunity, driven by the need for industry consolidation and the emergence of new integration models [6][7] - The development of merger funds is seen as a solution to the "exit difficulty" faced by private equity investments, with only 7% of exits in 2024 occurring through mergers compared to more mature markets [7] - The active participation of private equity funds in mergers is increasing, with a 22.88% year-on-year growth in transaction value involving private equity funds [8] Group 4 - The establishment of a national-level merger fund is viewed as a milestone, signaling a new development paradigm that integrates national strategic capital with market-driven operations to enhance industrial competitiveness [9] - The focus on deep integration and upgrading of industries aims to foster globally competitive industry leaders in key sectors such as integrated circuits, biomedicine, and artificial intelligence [9]

Group 1 - The core point of the news is the performance of the Science and Technology Innovation Pharmaceutical ETF (工银, 588860), which opened with a gain of 0.48% at 0.626 yuan on March 24 [1][2] - The ETF's major holdings showed positive movements, with notable increases including Zai Lab (泽璟制药) up 2.81%, BeiGene (百济神州) up 1.90%, and Honor Bio (荣昌生物) up 2.70% [1] - The ETF's performance benchmark is the Shanghai Stock Exchange Science and Technology Innovation Board Biopharmaceutical Index, managed by ICBC Credit Suisse Asset Management Company, with a return of 24.70% since its inception on August 8, 2024, and a recent one-month return of -10.90% [2] Group 2 - The MACD golden cross signal has formed, indicating a positive trend for the stocks mentioned [3]

Real Estate - In January-February 2026, the supply of residential land in 100 cities decreased by 17% year-on-year, while the transaction area dropped by 34%, and the average transaction floor price fell by 24% year-on-year [1] - In the core 30 cities, 9 plots of land were sold with a premium rate exceeding 20%, accounting for 11.1%, while 68 plots were sold at zero premium, making up 84.0% of the total transactions, indicating low transaction volume and prices [1] - The report recommends companies such as China Jinmao and Greentown Service as the market continues to stabilize with the implementation of previous policies [1] Real Estate - High-Frequency Tracking - As of March 22, 2026, new home transactions in 20 cities totaled 114,000 units, down 28.8% year-on-year, with Beijing at 5,452 units (-31%), Shanghai at 17,000 units (-13%), and Shenzhen at 3,193 units (-58%) [2] - For second-hand homes in 10 cities, total transactions reached 200,000 units, a decrease of 7.3% year-on-year, with Beijing at 35,000 units (-4%), Shanghai at 56,000 units (-0.2%), and Shenzhen at 11,000 units (-14%) [2] Oil and Gas - Company Research - In 2025, the company achieved total revenue of 27.2 billion yuan, a decrease of 9.3% year-on-year, and a net profit attributable to shareholders of 2.084 billion yuan, down 3.6% year-on-year [3] - The forecast for net profit attributable to shareholders for 2026-2028 is 2.436 billion, 2.733 billion, and 3.020 billion yuan respectively, indicating an improvement in profitability [3] Oil and Gas - Sinopec - In 2025, the company reported total revenue of 2.7836 trillion yuan, down 9% year-on-year, and a net profit attributable to shareholders of 31.8 billion yuan, a decline of 37% [4] - The forecast for net profit attributable to shareholders for 2026-2028 is 403 billion, 471 billion, and 556 billion yuan, with expectations of performance improvement as new capacity comes online and investments in the new energy sector materialize [4] Building Materials - The company anticipates an improvement in the supply-demand structure for coarse yarn in 2026, with a positive price trend for electronic fabrics, leading to an upward revision of net profit forecasts for 2026-2027 to 5.52 billion and 6.39 billion yuan respectively [5] Jewelry - Chow Tai Fook - The company is the largest gold and jewelry company in China, facing challenges due to weak retail demand and rising gold prices, leading to a reduction in franchise stores [7] - The company is optimizing inefficient stores and has seen a positive quarterly same-store sales growth in the second half of 2025, with projected net profits for FY2026-2028 of 8.131 billion, 8.980 billion, and 9.547 billion yuan respectively [7] Pharmaceuticals - Tian Tan Biology - The company has received a high-tech enterprise certificate for its subsidiary, emphasizing its commitment to innovation and research [8] - The product pipeline is expanding, with several products making progress in the approval stages, which is expected to strengthen the company's leading position in the recombinant coagulation factor and immunoglobulin sectors [8]

Core Viewpoint - The recent advancements in mRNA vaccines and genome editing therapies rely on the development and engineering of lipid nanoparticles (LNPs), which are non-viral delivery systems that effectively protect nucleic acids and deliver them to cells [3][4]. Group 1: Development of Targeted Delivery Systems - The research team led by Professor Daniel Siegwart developed organ-specific targeting LNPs, known as SORT-LNP, which enable mRNA delivery to organs outside the liver, such as the lungs and kidneys [3]. - A new study published in Nature Biomedical Engineering introduced tripod-like lung-targeting (LuT) lipids for constructing novel LNPs, achieving highly efficient and selective gene delivery and editing to the lungs [4]. Group 2: Design and Evaluation of LuT Lipids - The study systematically described the design, chemical synthesis, and biomedical evaluation of two lipid libraries, resulting in the synthesis of 444 quaternary ammonium lipids [7]. - The optimal LuT lipid features a unique "tripod-like" structure, consisting of a quaternary ammonium head as the core, three long alkyl chains as "legs," and a short chain as a "handle" [7]. - The screening process yielded a high success rate, with 39% of candidates from the first library and 67% from the second library demonstrating excellent performance [7]. Group 3: Performance and Implications of LuT LNPs - The best-performing LuT LNP, named 1A7B13 LNP, showed a 25.5-fold increase in mRNA delivery efficiency compared to the benchmark DOTAP SORT LNP and a 9.2-fold increase in gene editing efficiency using CRISPR–Cas9, with over 90% selectivity for lung delivery [9]. - The delivery of IL-10 mRNA via 1A7B13 LNP demonstrated promising therapeutic effects for acute lung injury, highlighting the relationship between lipid structure and lung-targeting activity [9].

Core Viewpoint - The article emphasizes the significant role of commercial health insurance in promoting the development of innovative drugs and medical devices, highlighting its potential to alleviate patients' financial burdens and enhance the accessibility of high-value medical services [1][3][4]. Group 1: Development of Commercial Health Insurance - The government report during the Two Sessions called for accelerating the development of commercial health insurance to better meet diverse medical needs [1][2]. - The insurance industry sees the government's focus on commercial health insurance as an opportunity to stimulate market participants to enhance its development and facilitate medical innovation [2][3]. - Commercial health insurance is viewed as a crucial component of a multi-tiered medical security system, effectively addressing the economic pressures faced by patients [2][3]. Group 2: Challenges in Implementation - Despite the establishment of the commercial health insurance innovative drug directory, challenges remain in the practical application of innovative drugs, particularly in hospitals [6][7]. - Issues such as the "last mile" problem, where innovative drugs face difficulties in hospital access and prescription availability, hinder their effective use [6][7]. - The lack of clinical guidelines and the limited willingness of hospitals to adopt these drugs contribute to the low utilization rates of the commercial health insurance directory drugs [6][7]. Group 3: Financial Implications and Market Dynamics - In 2024, the total compensation amount for innovative drugs under commercial health insurance is projected to be approximately 12.4 billion yuan, with a significant portion coming from government-led initiatives [4]. - The introduction of the commercial health insurance innovative drug directory allows for a dual-track payment system, where commercial insurance complements basic medical insurance by covering high-value innovative drugs [5][6]. - The insurance industry faces challenges in pricing and risk management due to a lack of comprehensive data on innovative drugs, which complicates the development of related insurance products [8][9]. Group 4: Recommendations for Improvement - Suggestions include accelerating the inclusion of public hospitals in the commercial health insurance innovative drug directory and establishing a dynamic adjustment mechanism for the directory [9][10]. - Enhancing the payment levels of commercial health insurance for innovative drugs is crucial, with recommendations for reforming funding models and improving efficiency [10][11]. - The establishment of a collaborative governance model involving insurance companies in the development of clinical guidelines for high-value innovative drugs is proposed to improve accessibility and affordability [9][10].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 茲提述：(i)本公司日期為2023年2月8日及2023年3月9日之公告，內容有關本公 司全資子公司上海昊海醫藥科技發展有限公司（「受讓方」）自張勁松先生、深圳市 九思投資合夥企業（有限合夥）、中經股權投資基金管理（深圳）合夥企業（有限合 夥）以及深圳市百納通達投資諮詢合夥企業（有限合夥）（合稱「前轉讓方」）收購深 圳市新產業眼科新技術有限公司（「目標公司」）20%股權的《股權轉讓協議》（「《股 權轉讓協議》」）；以及(ii)本公司日期為2025年11月7日之公告（「公告」），內容有 關受讓方自張勁松先生、深圳市九思投資合夥企業（有限合夥）以及深圳市百納通 達投資諮詢合夥企業（有限合夥）（合稱「轉讓方」）訂立《股權轉讓補充協議》（「《股 權轉讓補充協議》」），以收購深圳新產業剩餘20%的股權。除非另有界定，否 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容引致的任何損失承擔任何責任。 GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2595） 前瞻性聲明 自願公告 將於 2026 年 AACR 年會上展示三款 RAS 通路相關的 大、小分子靶向藥臨床前研究數據 本公告由勁方醫藥科技（上海）股份有限公司（「本公司」或「勁方」，連同其附 屬公司統稱「本集團」）自願刊發，以知會本公司股東及潛在投資者有關本集團 最新業務動態。 本公司董事會（ 「董事會」）宣佈，本公司將於 2026 年 AACR 年會壁報環節展示 GFH276 （非降解性分子膠）、GFS784 （新型偶聯藥物，連接功能性抗體及機制協 同性靶向藥載荷）、GFH603 （類分子膠共價變構激活劑）三款產品的臨床前研究 數據 。本公司 RAS 療法矩陣聚焦多種選擇性和泛 RAS 抑制劑 ，亦持續關注 RAS 通路重要共突 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Insights - The company reported a revenue of 793 million yuan for 2025, representing a year-on-year growth of 15.49%. The net profit attributable to the parent company was 144 million yuan, up by 31.49%, while the net profit excluding non-recurring items reached 118 million yuan, increasing by 55.80% [4][6]. - The company's internationalization strategy is yielding results, with overseas sales growing significantly. In the first three quarters of 2025, overseas revenue reached 107 million yuan, a year-on-year increase of 23.62%, with Q3 alone showing a remarkable growth of 63.97% [4][6]. - Domestic demand is recovering, particularly in the functional pharmaceutical sector, driven by increased R&D investments from downstream industrial clients. The company has leveraged its technological advantages to achieve rapid growth in this area [4]. Financial Performance - The company is expected to achieve revenues of 923 million yuan and 1.074 billion yuan in 2026 and 2027, respectively, with growth rates of 16% for both years. The net profit attributable to the parent company is projected to be 171 million yuan in 2026 and 202 million yuan in 2027, reflecting year-on-year growth of 19% and 18% [6][8]. - The company's earnings per share (EPS) is forecasted to increase from 0.35 yuan in 2025 to 0.49 yuan in 2027, indicating a positive trend in profitability [8][9]. - The report highlights a significant improvement in profitability, with the net profit growth rate outpacing revenue growth due to new production capacity and effective cost control [5].